{"entity":{"id":"peluntamig","kind":"drug","name":"Peluntamig","aka":["Peluntamig (PT217)"],"tldr":"Peluntamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and neuroendocrine tumours, aimed at CD47 and DLL3.","summary":"Peluntamig (PT217) is a bispecific antibody developed by Phanes Therapeutics. Its targets are CD47 and DLL3. ClinicalTrials.gov describes the intervention as: A bispecific antibody (bsAb) against DLL3 and CD47. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and neuroendocrine tumours. The largest, NCT05652686, plans to enrol 203 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Peluntamig","url":"https://clinicaltrials.gov/search?intr=PT217"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","neuroendocrine","extrapulmonary-nec"],"sections":[],"technologies":[],"targets":["cd47","dll3"],"drugs":[],"companies":["phanes-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05652686"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"PT217","modality":"bispecific antibody","mechanism":"Bispecific antibody directed at CD47 and DLL3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/peluntamig/","neighbours":{"cancer":[{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/"},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"}],"company":[{"id":"phanes-therapeutics","kind":"company","name":"Phanes Therapeutics","route":"/companies/phanes-therapeutics/"}],"trial":[{"id":"nct05652686","kind":"trial","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","route":"/trials/nct05652686/"}],"drug":[{"id":"obrixtamig","kind":"drug","name":"Obrixtamig","route":"/drugs/obrixtamig/"}]}}